RECENTLY ADDED
Treatment of Opioid Use Disorder: Waiver Qualifying - ACOG - Fort Worth, TX - Friday, November 9, 2018
Contains 24 Component(s), Medical Credits OfferedThe ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements will ensure that participants are exposed to the highest quality, evidence-based practices when using buprenorphine to treat opioid use disorders.
Friday, November 9, 2018 | 9:00 am - 1:30 pm
The Women's Center
1723 Hemphill St.
Fort Worth, TX 76110Cost: $75
This course is offered in partnership with the American College of Obstetricians and Gynecologists. The curriculum for this course has been specifically designed for women's health providers.
Welcome to the ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off the content delivered in the online portion. Course faculty are expecting you to come to the live course with the online portion completed.
Getting started: To begin the online portion of the course, please log in to your right and locate the box that says Module 1. If you do not know your password, or you have forgotten it, select Forgot Password and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.
Once you have completed the 4-hour online portion and the 4-hour live portion of the course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
Apply
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.
Apply
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
CME Information and Disclosure Listing
Date of Release: July 2015
Approved Through: July 2018The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The combined online enduring material and live activity will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Catherine R. Friedman, MD, FASAM Chair
None
Edwin A. Salsitz, MD, FASAM
None
Herbert Malinoff, MD, FACP, FASAM
None
Noel Ilogu, MD, MRCP
None
Abigail Kay, MD
None
John Tanner, DO, FASAM
Reckitt Benckiser
OREXO
BDSI
Honorarium
Honorarium
Honorarium
Speaker
Speaker
Speaker and Consultant
Catherine Friedman, MD
None
ASAM Buprenorphine Program Planning Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Dan Alford, MD, MPH
None
Andrew J. Saxon, MD
UpToDate
Royalties
Section Editor, Drug Use Disorders
Colleen LaBelle, BSN, RN-BC, CARN
None
Edwin Salsitz, MD, FASAM
None
Jeffrey D. Baxter, MD
None
Kelley Saia, MD
None
Sharon Levy, MD, MPH
None
Paula J. Lum, MD, MPH
None
ASAM Buprenorphine Course FacultyName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Edwin Salsitz, MD, FASAM
None
Andrew J. Saxon, MD
UpToDate
Royalties
Senior Editor, Drug Use Disorders
Colleen LaBelle, BSN, RN-BC, CARN
None
Dan A. Alford, MD, MPH
None
Jeffrey D. Baxter, MD
None
Kelley Saia, MD
None
Sharon Levy, MD, MPH
None
Paula J. Lum, MD, MPH
None
Sarah Bagley, MD
ASAM Millennium Fellowship Award
Partial Salary Support
Awardee
Alexander Y. Walley, MD, MSc
None
ASAM CME Committee Reviewers
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Adam J. Gordon, MD, MPH, FACP, FASAM
None
Herbert Malinoff, MD, FACP, FASAM
None
Learners will be able to:
- Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
- Identify and assess patients who are appropriate for treatment with medications
- Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
- Discuss the psychiatric and medical co-morbidities associated with opioid addiction
- Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
- Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
- Continue to Module 1 Part 2 and Module 1 Part 3
- Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
- After you have completed Module 1 Quiz, continue to modules 2 and 3
- You will be required to pass all 3 Module Quizzes with a grade of 70% or higher
- Upon completion of both the 4 online hours and 4 live hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center
- Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
- Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.
ASAM Review Course Spotlight Webinar Series 2018 (6 CME)
Contains 24 Component(s), Medical Credits OfferedRegister now to earn a maximum of 6 CME while attending this six-webinar series, which will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine 2018. Topics include; psychiatric co-morbidities, cannabis, tobacco, prevention and public health, pharmacology and toxicology, and pain and addiction.
REVIEW COURSE ATTENDEES RECEIVE 25% OFF - Use the promo code located in your syllabus when checking out to take advantage of this special deal!
Looking to stay engaged and expand your ASAM Review Course experience? This six-webinar series will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine.
Each webinar will be an hour long, with 30-45 minutes of lecture on the topic of the week and the rest saved for audience questions. Questions have been collected in advance from participants of the 2018 Review Course and all attendees will have the opportunity to submit questions during the live webinar!
All webinars will be recorded and available to watch for registrants unable to attend live.
Date Time (Eastern) Topic Tuesday, August 28 12:00 pm – 1:00 pm Cannabis
Carla Marienfeld, MDThursday, August 30 12:00 pm – 1:00 pm Tobacco
Abigail Herron, DO, FAPA, DFASAMWednesday, September 5 12:00 pm – 1:00 pm Prevention and Public Health
Sharon Stancliff, MD, FASAMFriday, September 7 12:00 pm – 1:00 pm Pharmacology and Toxicology
Timothy Wiegand, MD, FACMT, FAACTMonday, September 10 12:00 pm – 1:00 pm Pain and Addiction
Edwin Salsitz, MD, DFASAMWednesday, September 12 12:00 pm – 1:00 pm Psychiatric Co-Morbidities
Richard Ries, MD, DFASAM
Additional ResourcesAdditional Board Exam Preparation resources and tools are also available.
Edwin A. Salsitz
MD, DFASAM
Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.
Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids.
Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services. Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.
Richard K. Ries
MD, DFASAM
Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident.
Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine. A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and holds a number of research grants from the National Institute of Health.
He has published numerous articles and abstracts on topics related to treatment of persons with severe mental illness, with special emphasis on those with co-existing problems with alcohol or drugs, and was the chair and co-chair of TIPS 9 and 42 on Treatment of Persons with Co-occurring Addiction and Mental Disorders published by the national Center of Substance Abuse Treatment (CSAT). He is senior editor of the key reference text: Principles of Addiction Medicine (edition V, 2014), published by the American Society of Addiction Medicine, and a noted expert in the field of Addictions.
Carla Marienfeld
MD
Carla Marienfeld, MD, is an addiction psychiatrist and an Associate Clinical Professor of Psychiatry at University of California San Diego. Clinically, she focuses on the treatment of patients with substance use disorders and co-morbid psychiatric conditions. She previously worked at a large outpatient addiction treatment program serving over 5000 patients. Her academic interests focus on implementation research and large-data health outcomes for patients with substance use disorders. She attended Baylor College of Medicine in Houston, TX, where she completed the International Health Track, served nationally on the Board of Trustees of the American Medical Student Association (AMSA), and earned Alpha Omega Alpha (AOA) Medical Honors Society and Honors distinction. During psychiatry residency at Yale, she served as chief resident, a National Institute of Drug Abuse R25 Research Fellow, and as the resident representative to the Accreditation Council for Graduate Medical Education (ACGME), while also earning several awards and fellowships. She completed a fellowship in Addiction Psychiatry at Yale. During residency and her early faculty years, she founded and led the Yale Global Mental Health Program. She served as the site training director for the Yale New Haven Hospital Addiction Psychiatry Fellowship and supervised and taught medical students for psychiatry, residents for global mental health, and fellows for addiction psychiatry. She has come to UCSD to help in the development and implementation of a new Addiction Recovery and Treatment Program and a new Addiction Psychiatry Fellowship.
Abigail J. Herron
DO, DFASAM, FAPA
Abigail J. Herron, DO, is the Director of Psychiatry and the Director of the Fellowship in Addiction Medicine at the Institute for Family Health. She is board certified in adult psychiatry, addiction psychiatry and addiction medicine, and is an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mt. Sinai.
Dr. Herron is a fellow of the American Psychiatric Association and a Distinguished Fellow of the American Society of Addiction Medicine. She graduated from Wesleyan University and the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine. Dr. Herron completed her psychiatry residency at St. Luke's and Roosevelt Hospitals, where she was also chief resident, and a clinical research fellowship in addiction psychiatry at Columbia University and the New York State Psychiatric Institute.
Her academic interests include integrated care, women’s health, and medical education. She is the co-editor of the Addiction Casebook, and the editor-in-chief of ASAM’s Essentials of Addiction Medicine. Dr. Herron is also in private practice in New York City.
Sharon Stancliff
MD, FAAFP
Sharon Stancliff, M.D. is the Medical Director of the Harm Reduction Coalition She oversees SKOOP, which provides overdose prevention services both directly in New York City and through education and capacity building nationally and internationally. Dr. Stancliff also consults on drug related problems for the AIDS Institute, New York State Department of Health and for several international organizations.
Dr. Stancliff graduated from the School of Medicine at University of California at Davis, did her Family Practice residency at the University of Arizona and completed the AIDS Institute-sponsored Nicolas Rango HIV Clinical Scholars Program at Beth Israel Medical Center in New York City. She is board certified in Family Medicine, a Fellow of the American Academy of Family Practice, and certified by the American Board of Addiction Medicine. She serves as secretary for the New York Society of Addiction Medicine.
Timothy J. Wiegand
MD, FACMT, FAACT, FASAM
Tim Wiegand MD, DABAM, FACMT, FAACT was trained in internal medicine and completed fellowship training in Medical Toxicology at the University of California, San Francisco in 2006. He was the Medical Director of the Rochester Poison Center until 2010. Dr. Wiegand has been successful in developing a full time, bedside, medical toxicology consultation service and is very active in the practice of Addiction Medicine, having successfully completed his board certification recently.
In addition to his primary appointment as Associate Professor of Emergency Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, NY, Dr. Wiegand serves as Medical Director for Huther Doyle Chemical Dependency Treatment Program in Rochester, NY and as a detoxification specialist for Syracuse Behavioral Health in Rochester, NY.
Dr. Wiegand serves on the New York Society of Addiction Medicine (NYSAM) Board of Directors as the Communication Committee Chair and he was recently elected to the American College of Medical Toxicology Board of Directors to begin a 3 year term in October, 2015. He currently serves as the chair of the Addiction Medicine Section for the American College of Medical Toxicology and he recently organized a very successful Addiction Medicine Academy for ACMT prior to their main Annual Scientific Meeting in Clearwater, Florida in March, 2015. Dr. Wiegand has presented for the ASAM Review Course on Pharmacology & Toxicology, MRO and drug testing principles at previous Review Course conferences.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 6 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 6 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 6 AMA PRA Category 1 Credit(s)™ for completing this course.
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The ASAM CME Committee and Reviewers Disclosure Listing
Name
Commercial Interest
What was received?
For what role?
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair
None
Catherine Friedman, MD
Vice Chair
None
Noel Ilogu, MD, MRCP, DFASAM
None
Hebert L. Malinoff, MD, FACP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO
Indivior
BDSI
Honorarium
Honorarium
Speaker
Consultant/Speaker
The ASAM Review Course Program Planning Committee Disclosure Listing
Name
Commercial Interest
What was received?
For what role?
Petros Levounis, MD, MD, DFASAM
None
Abigail Herron, DO, DFASAM, FAPA
None
Timothy K. Brennan, MD, MPH, FASAM
None
David Galbis-Reig, MD, DFASAM
Abbot Pharmaceuticals
AbbVie
Cortex Pharmaceuticals
GW Pharmaceuticals
Hospira
Pfizer, INC
Ownership Interest
Ownership Interest
Ownership Interest
Ownership Interest
Ownership Interest
Ownership Interest
Stock Options
Stock Options
(spouse)
Stock Owned through IRA Rollover Account
Stock Owned through IRA Rollover Account
Stock Options
(Spouse)
Bonds in IRA
Carla Marienfield, MD
None
Ricardo Restrepo, MD, MPH
None
Edwin A. Salsitz, MD, DFASAM
None
Erin Zerbo, MD
None
The ASAM Review Course Faculty Member Disclosure Listing
Name
Commercial Interest
What was received?
For what role?
Petros Levounis, MD, MD, DFASAM
None
Abigail Herron, DO, DFASAM, FAPA
None
Timothy K. Brennan, MD, MPH, FASAM
None
Jeffrey DeVido, MD, MTS
Philip Morris
Altria
Ownership Interest
Ownership Interest
Equity Shareholder
Equity Shareholder
Paul H. Earley, MD, DFASAM
Alkermes
Georgia PHP, INC
Earley Counsultancy, LLC
DynamiCare Health, INC
Honoraria
Salary
Salary
Salary
Speaker
Medical Director
Principal
Speaker
James W. Finch, MD, DFASAM
Orexo Pharmaceuticals
Indivior Pharmaceuticals
Honoraria
Honoraria
Speaker
Speaker
Marc Fishman, MD, DFASAM
Alkermes
US WorldMeds
MediaRez
Salary
Salary
Research Funding
Consultant; Advisory Board
Consultant; Advisory Board; Principal Research Investigator
Principal Research Investigator
David Galbis-Reig, MD, DFASAM
Abbot Pharmaceuticals
AbbVie
Cortex Pharmaceuticals
GW Pharmaceuticals
Hospira
Pfizer, Inc
Ownership Interest
Ownership Interest
Ownership Interest
Ownership Interest
Ownership Interest
Ownership Interest
Stock Options
Stock Options
(spouse)
Stock Owned through IRA Rollover Account
Stock Owned through IRA
Rollover Account
Stock Options
(Spouse)
Bonds in IRA
Leslie Hayes, MD
None
Carla Marienfield, MD
None
Ricardo Restrepo, MD, MPH
None
Richard Ries, MD, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
Sharon Stancliff, MD
None
Timothy J. Wiegand, MD, FACMT, FAACT, FASAM
None
Erin Zerbo, MD
None
The ASAM Review Course in Addiction Medicine 2018 (20.5 CME)
Contains 24 Product(s)Earn up to 20.5 CME while preparing for the ABPM Addiction Medicine Exam using this on-demand package of courses, containing the conference recordings, resources, practice questions, and slides from The ASAM Review Course in Addiction Medicine, 2018. The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.
Overview
The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.
The course offers two and a half days of sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. Over 600 professionals attend this popular course each time it is offered. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.
Learning Objectives
Upon completion, participants should be able to:
- Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
- Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
- Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
- Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
- Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse
Additional Resources
Additional Board Exam Preparation resources and tools are also available.
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The ASAM CME Committee and Reviewers Disclosure Listing
First Name Commercial Interests Compensation Received For what Role? Timothy Brennan MD, MPH, FASAM None Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs James Finch MD, DFASAM None Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests Owner; Advisory board; PI; Consultant Adam Gordon, MD, MPH None Leslie Hayes, MD None Abigail Herron DO, DFASAM None Petros Levounis MD, MA, FASAM None Carla Marienfeld MD None Ricardo Restrepo MD, MPH, FASAM None Richard Ries MD, DFASAM None Edwin Salsitz MD, DFASAM None Sharon Stancliff MD, FASAM None Timothy Wiegand MD, FACMT, FAACT None Erin Zerbo, MD None ACCME Accreditation Statement:
The American Society of Addiction Medicine is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing medical education for physicians.AMA Credit Designation Statement:
The American Society of Addiction Medicine designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Academy of Family Physicians:
This Live activity, The 2018 ASAM Review Course in Addiction Medicine & Pre-Courses, with a beginning date of 07/25/2018, has been reviewed and is acceptable for up to 27.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABAM Transitional Maintenance of Certification Program (Tmoc)
This course has been approved by The American Board of Addiction Medicine (ABAM). Physicians enrolled in the Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 20.5 AMA PRA Category 1 Credits™
American Psychological Association (APA)
The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
CME Committee Members
- Catherine Friedman, MD, FASAM, Chair
- R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM
- Adam J. Gordon, MD, MPH, FACP, DFASAM
- Zwaantje Hamming, FNP-C, CARN-AP
- Noel Ilogu, MD, MRCP, FASAM
- Herbert L. Malinoff, MD, FACP, DFASAM
- Edwin A. Salsitz, MD, DFASAM
Staff - Sandy Metcalfe; Arlene Deverman, MA, CAE, CFRE; Marcia Jackson, PhD
CME Committee, Program Planning Committee and Faculty Disclosure Information
In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 20.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 20.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 20.5 AMA PRA Category 1 Credit(s)™ for completing this course.
Upon completion, participants should be able to:
- Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting.
- Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals.
- Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders.
- Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient.
- Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse.
The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:
- Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
- Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
- Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients
Pain Management and Opioids: Balancing Risks and Benefits (2.5 CME)
Contains 5 Component(s), Medical Credits Offered Recorded On: 07/25/2018Earn a maximum of 2.5 AMA PRA Category 1™ Credit(s) while reviewing prescribing habits and examine the difference between extended release/long acting medications to help ensure patient safety and effective pain management.
The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:
- From 2000 to 2015 more than half a million people died from drug overdoses.
- 91 Americans die every day from an opioid overdose.
The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. The updated course also provides necessary context for safe opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids.
Learners will be able to:
- Accurately assess patients with pain for consideration of an opioid trial
- Establish realistic goals for pain management and restoration of function
- Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
- Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
- Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
- Educate patients about safe storage and disposal of opioids
- Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice.
Edwin A. Salsitz
MD, DFASAM
Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.
Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids.
Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services. Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.
CME Information and Disclosure Listing
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.
The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Catherine R. Friedman, MD, FAPA, DFASAM, Chair
None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM
None
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
None
Zwaantje Hamming, FNP-C, CARN-AP
None
Noel Ilogu, MD, MRCP, DFASAM
None
Hebert L. Malinoff, MD, FACP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
ASAM Staff and Consultants:
Arlene C. Deverman, MA, CAE, CFRE
None
Marcia Jackson PhD
None
Sandy Metcalfe
None
Program Planning Committee
Faculty
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Herbert Malinoff, MD, FACP, DFASAM
None
Yngvild Olsen, MD, MPH
None
Theodore Parran, MD, FACP
None
Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, FACEP
None
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Edwin A. Salsitz, MD, DFASAM
None
ASAM CME Committee Reviewers
ASAM Medical Education CouncilName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Jacob Bobrowski, MD, FAAFP
None
Anthony H. Dekker, DO, DFASAM
None
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Peter Selby, MBBS, CCFP, FCFP, MHSc, DipABAM, DFASAM, Chair
Pfizer
Johnson & Johnson
Pfizer Canada
Grant funding
Consulting Fees
Consulting Fees
Principal Investigator
Consulting
Consulting
Daniel Alford, MD, MPH
None
Michael Fingerhood, MD, FACP, FASAM
None
Catherine R. Friedman, MD, FAPA, DFASAM
None
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
None
Miriam S. Komaromy, MD, FACP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
Mark P. Schwartz, MD, DFASAM
None
Mark A. Weiner, MD, FASAM
None
ASAM Staff and Consultants:
Arlene C. Deverman, MA, CAE, CFRE
None
Marcia Jackson PhD
None
Jennifer L. Butchart
None
Penny S. Mills, MBA
None
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 2.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 2.5 AMA PRA Category 1 Credit(s)™ for completing this course.
Acknowledgement
Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.
RPC Commercial Support Disclosure Statement
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.
This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.
Board Exam Study Tool (BEST) - 2018 (12 CME)
Contains 5 Component(s), Medical Credits OfferedEarn a maximum of 12 CME while learning from the BEST. This study tool helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format.
The ASAM Board Examination Study Tool (BEST) helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format.
This powerful study tool includes:
- Bank of 600 self-assessment questions reviewed for accuracy by addiction medicine experts
- Content derived from the ABPM Exam Blueprint for effective study guidance
- Excerpts and highlights from ASAM’s Essentials of Addiction Medicine and Principles of Addiction Medicine
- Glossary of important terms and definitions
- Additional resources recommended by Review Course faculty and experts for each topic
- 12 CME Credits upon completion
- Fully searchable functionality and content
- Access to the BEST 24/7 online at ASAM's e-Learning Center
Live attendees of the 2018 ASAM Review Course in Addiction Medicine in Dallas, TX receive the 2018 BEST complimentary with registration.
Additional Board Exam Preparation resources and tools are also available.
Goals and Objectives
Upon completion of this education activity, participant should be able to:
- Differentiate between important terms and definitions in the field of Addiction Medicine.
- Distill knowledge on key points from the text, the Principles of Addiction Medicine, 5th edition and course slides
- Appraise addiction patient cases and respond accurately to questions about next steps and treatment options.
- Employ knowledge gained in the educational sections of the BEST to respond accurately to self-assessment questions.
Participants of the 2018 ASAM Review Course in Addiction Medicine and other physicians who are preparing for the ABPM Certification Exam in Addiction Medicine.
First Name Commercial Interests Compensation Received For what Role? Timothy Brennan MD, MPH, FASAM None Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs James Finch MD, DFASAM None Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests Owner; Advisory board; PI; Consultant R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None Adam Gordon, MD, MPH None Leslie Hayes, MD None Abigail Herron DO, DFASAM None Petros Levounis MD, MA, FASAM None Carla Marienfeld MD None Ricardo Restrepo MD, MPH, FASAM None Richard Ries MD, DFASAM None Edwin Salsitz MD, DFASAM None Sharon Stancliff MD, FASAM None Timothy Wiegand MD, FACMT, FAACT None Erin Zerbo, MD None ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 12 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 12 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 12 AMA PRA Category 1 Credit(s)™ for completing this course.
